 Home > Active Ingredient News > Antitumor Therapy > A new breakthrough in the treatment of KRAS G12C mutant cancers, a new combination of KRAS inhibitors shows positive results

A new breakthrough in the treatment of KRAS G12C mutant cancers, a new combination of KRAS inhibitors shows positive results

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

paxil 20 mg

mcl 1 inhibitor

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Amgen announced the latest results of an early study that evaluated the effectiveness and safety of Lumakras (sotorasib) in combination with more than a dozen different drugs in the treatment of KRAS G12C mutant cancers (Figure 1)
.

Figure 1.
Test drugs in Phase Ib CodeBreaK 101 study

A branch of the Phase Ib CodeBreaK 101 study-evaluating Lumakras in combination with afatinib-recruited 33 patients with KRAS G12C mutant non-small cell lung cancer ( NSCLC ) who had undergone a large number of previous treatments , including 5 patients who had previously received Lumakras monotherapy
.

NSCLC

The researchers gave 10 patients 20 mg of afatinib combined with 960 mg of Lumakras, while 23 patients received 30 mg of afatinib and 960 mg of Lumakras
.

The data showed that the overall response rate (ORR) of the first cohort was 20%, the ORR of the second cohort was 35%, and the disease control rates of the two cohorts were 70% and 74%, respectively

The researchers gave 10 patients 20 mg of afatinib combined with 960 mg of Lumakras, while 23 patients received 30 mg of afatinib and 960 mg of Lumakras

Colorectal cancer

Among patients with CRC who were not treated with KRAS G12C inhibitors, 9% achieved partial remission and 82% achieved disease control
.

At the same time, 14% of CRC patients who had previously received treatment achieved partial remission, and 86% of patients achieved disease control

In the NSCLC population, 20% of KRAS G12C inhibitor-naive patients achieved partial remission, and 87% achieved disease control
.

Among patients previously treated with KRAS G12C inhibitors, 67% achieved disease control

David M.
Reese, Executive Vice President of Research and Development at Amgen, said: “Amgen will consider the results of these afatinib and trametinib
.

We look forward to showing more data in the coming months, including data sets combined with PD-1 inhibitors

Original source:

http:// href="http://" target="_blank" rel="noopener">http:// http:// Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.